Lung cancer treatment typically costs between $25,000 and $250,000 or more over the course of care, depending on the stage at diagnosis and the types of treatment involved. Monthly costs during the initial treatment phase range from roughly $800 to $8,300 for Medicare patients, with surgery on the lower end and chemotherapy combined with radiation on the higher end. Those numbers reflect the cancer-related portion of care only, and the real total depends on your insurance, the drugs prescribed, and how long treatment continues.
Costs by Cancer Stage
The stage of lung cancer at diagnosis is one of the biggest factors driving total cost, because it determines which treatments you need and for how long. A study of Medicare enrollees published in Cancer Medicine broke down average monthly cancer-related costs during the first six months of treatment. For the most common type, non-small cell lung cancer (NSCLC), the numbers looked like this:
- Stages I and II treated with chemotherapy and radiation: about $4,200 per month
- Stage III treated with chemotherapy alone: about $8,100 per month
- Stage III treated with chemotherapy and radiation: about $7,500 per month
- Stage IV treated with chemotherapy and radiation: about $8,300 per month
For small cell lung cancer, which grows faster and is usually treated with chemotherapy, monthly costs ranged from $6,200 to $7,400 regardless of whether the disease was limited or extensive. These figures represent the cost attributable to cancer care specifically, not total medical spending, and they held steady or increased over the treatment period for most patients.
Surgery Costs
When lung cancer is caught early enough for surgery, the upfront cost is significant, but the ongoing monthly expenses tend to be much lower. The average 90-day cost of a lobectomy (removing a lobe of the lung, the most common surgical approach) is about $45,000, based on an analysis combining data from the Society of Thoracic Surgeons and Medicare claims. After recovery, cancer-related costs for surgical patients dropped to roughly $828 per month during the initial follow-up phase. That’s a fraction of what chemotherapy or radiation costs on a monthly basis, which is one reason early detection makes such a financial difference.
Chemotherapy and Radiation
Chemotherapy is the backbone of treatment for most lung cancer patients, especially those diagnosed at stage III or IV. Monthly chemotherapy costs ranged from $6,200 to $8,100 depending on cancer type and stage. When radiation was added, total monthly costs generally stayed in a similar range, between $7,000 and $8,300 per month. Treatment typically runs for four to six cycles, meaning the initial phase alone can span several months of these costs.
For patients who receive radiation alone or as a primary treatment, newer approaches can actually reduce costs. Stereotactic ablative radiotherapy (SABR), which delivers high doses in just 5 to 8 sessions, costs between $2,800 and $3,800 total. Conventional radiation therapy, delivered over 30 to 33 sessions, costs $5,600 to $6,100. SABR is typically used for early-stage patients who aren’t candidates for surgery, and it requires fewer trips to the treatment center.
Targeted Therapy and Immunotherapy
Newer drug therapies have transformed survival rates for certain lung cancer patients, but they come with substantial price tags. These are often taken for months or years, not just a few cycles.
Targeted therapies, which work on cancers with specific genetic mutations, vary widely in annual cost. Osimertinib, one of the most commonly prescribed drugs for a specific mutation found in some lung cancers, costs about $222,000 per year. Other drugs in the same category run between $113,000 and $147,000 annually. These are list prices before insurance, and not every patient needs them. Your oncologist will test your tumor for mutations to determine if targeted therapy is an option.
Immunotherapy drugs, which help your immune system recognize and attack cancer cells, are now standard for many lung cancer patients. The per-unit pricing varies by drug. Pembrolizumab (Keytruda), the most widely used immunotherapy in lung cancer, had an average sales price of about $53 per milligram in 2022, and its price has risen roughly 13% over recent years. A typical dose adds up to thousands of dollars per infusion, given every three to six weeks, often for up to two years. Other immunotherapy options have different pricing structures, but the annual cost for any of them generally runs into six figures before insurance adjustments.
Diagnostic and Staging Costs
Before treatment even begins, you’ll face costs for the tests needed to confirm a diagnosis and determine how far the cancer has spread. These include CT scans, PET scans, and biopsies. The cost of a biopsy varies enormously depending on the type and whether it’s done as an outpatient or requires a hospital stay.
An outpatient needle biopsy (percutaneous) has a median cost of about $1,030, making it the least expensive option. Outpatient bronchoscopy runs about $2,600, and outpatient mediastinoscopy costs around $3,700. If the biopsy requires an inpatient hospital stay, costs jump dramatically: inpatient needle biopsies have a median cost of about $9,100, while inpatient surgical biopsies average nearly $30,000. These figures include the associated CT scan and any complication costs. Most patients will need at least one biopsy plus multiple imaging scans before a treatment plan is set.
What Insurance Typically Covers
Most lung cancer treatment falls under medical insurance rather than prescription drug coverage, though oral targeted therapies are often billed through pharmacy benefits. For Medicare patients in 2026, Part B charges a monthly premium of $202.90, a $283 annual deductible, and then 20% coinsurance on covered services. That 20% adds up fast when monthly treatment costs run into the thousands. On a $7,500 monthly treatment bill, your coinsurance alone would be $1,500 per month.
Part D drug coverage, which handles oral medications, varies by plan. Premiums, deductibles, and copays differ depending on which plan you choose and which drugs you need. The Inflation Reduction Act introduced a cap on out-of-pocket drug costs for Medicare enrollees, and Medicare is now negotiating prices directly with drug manufacturers for some high-cost medications, with the first negotiated prices taking effect in January 2026.
Private insurance plans vary even more widely. Many have annual out-of-pocket maximums between $3,000 and $9,000 for individuals, which provides a ceiling on your direct costs. But reaching that maximum in a single year of cancer treatment is common.
Non-Medical Expenses
Treatment costs on paper don’t capture the full financial picture. Transportation to and from appointments, parking, meals during long treatment days, and lodging for patients who travel to specialized centers all add up. A 2022 analysis found that non-medical costs like transportation represented the majority of cancer patients’ monthly out-of-pocket spending, averaging $213 per month with a range up to nearly $600. Lost wages for both patients and family caregivers often dwarf even the medical bills, though those numbers vary too much by individual circumstance to pin down a useful average.
Financial Assistance Options
Several organizations offer grants specifically for lung cancer patients. The PAN Foundation, for example, provides copay assistance grants of $4,800 initially, with the possibility of up to $9,600 per year for non-small cell lung cancer patients who qualify based on income. Drug manufacturers also run patient assistance programs that can reduce or eliminate copays for specific medications. Your treatment center’s financial counselor or social worker can help identify which programs you’re eligible for, and it’s worth asking before treatment begins rather than after bills accumulate.